Which Cannabis Products Help Cancer Patients' Anxiety and Depression?
Among nearly 2,000 cancer patients in Minnesota's medical cannabis program, higher CBD doses and enteral (swallowed) products were associated with the most improvement in anxiety—while depression responded mainly to how cannabis was taken, not the dose.
Quick Facts
What This Study Found
This longitudinal study followed 1,962 cancer patients enrolled in the Minnesota Medical Cannabis Program, measuring self-reported anxiety and depression before and after 30 days of use. It's one of the largest studies to break down cannabis effects by dose, THC:CBD ratio, and route of administration.
For anxiety, the findings were dose-specific: patients taking higher CBD doses (>14.3 mg/day) showed more improvement than those taking lower doses (<4.6 mg/day). The route also mattered—enteral products (swallowed oils, capsules, edibles) outperformed other administration routes. And the THC:CBD ratio was relevant, though the specific pattern required a nuanced look at the data.
Depression followed a different pattern. Dose and THC:CBD ratio didn't significantly predict depression improvement—only the route of administration mattered, with enteral products again showing the most benefit.
The divergence between anxiety and depression is interesting: anxiety responded to dose, ratio, and route, while depression responded only to route. This suggests different mechanisms—CBD's anxiolytic effects may be dose-dependent, while depression improvement may relate more to the pharmacokinetic profile of swallowed products (slower onset, longer duration) than to the specific cannabinoid content.
The fact that enteral products outperformed others for both conditions has practical implications: patients seeking mental health benefits may do better with oils and capsules than with inhaled products.
Key Numbers
N = 1,962 cancer patients. 30-day follow-up. Higher CBD (>14.3 mg/day) better for anxiety than lower CBD (<4.6 mg/day). Enteral products better for both anxiety and depression. Depression responded to route but not dose or ratio.
How They Did This
Longitudinal cohort study. 1,962 cancer patients enrolled in the Minnesota Medical Cannabis Program. Self-reported anxiety and depression measured at enrollment and after 30 days. Analyzed by CBD dose (tertiles), THC:CBD ratio, and route of administration (enteral vs. other).
Why This Research Matters
Cancer patients increasingly use cannabis for anxiety and depression, but most do so without evidence-based guidance on what type to use. This study provides the first large-scale data suggesting that higher CBD doses and swallowed products may be optimal for anxiety—actionable information for patients and the clinicians advising them.
The Bigger Picture
This fills a gap in the cancer-cannabis evidence. RTHC-00158's RCT found no overall symptom benefit but specific pain improvement from THC:CBD. RTHC-00177's qualitative data captured patient-perceived appetite benefits. This study adds the mental health dimension, showing that how and what cancer patients take matters for psychological outcomes. The finding that enteral products outperform also connects to the bioavailability research in RTHC-00179—swallowed products produce different pharmacokinetic profiles than inhaled ones.
What This Study Doesn't Tell Us
Observational design within a medical cannabis program—patients chose their products (no randomization). Self-reported anxiety and depression (no clinical diagnosis). 30-day follow-up is relatively short. No control group (improvements could reflect placebo, natural recovery, or other treatments). Minnesota's program may have a specific product selection that limits generalizability. Dose data relies on product labels, not measured blood levels.
Questions This Raises
- ?Would a longer follow-up show sustained anxiety and depression benefits?
- ?Why does route matter more than dose for depression?
- ?Would these findings replicate in a randomized design with consistent products and doses?
Trust & Context
- Key Stat:
- Evidence Grade:
- Large longitudinal cohort from a state medical cannabis program—real-world data with meaningful sample size but limited by observational design and self-selection.
- Study Age:
- Published in 2025 in Cancer Medicine, reflecting current medical cannabis product options.
- Original Title:
- Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.
- Published In:
- Cancer medicine, 14(21), e71342 (2025) — Cancer Medicine is a reputable journal focused on oncology research.
- Authors:
- Reddy, Apoorva C(2), Hampton, John M(2), Park, Susan J(2), Dickerson, Faith, Shah, Janvi, Chewning, Betty, Schmitz, Natalie, Trentham-Dietz, Amy
- Database ID:
- RTHC-07455
Evidence Hierarchy
Follows a group of people over time to track how outcomes develop.
What do these levels mean? →Read More on RethinkTHC
- anxiety-leaving-house-weed-withdrawal-agoraphobia
- anxiety-response-technique-weed-withdrawal
- anxiety-toolkit-weed-withdrawal
- anxiety-worse-after-quitting-weed
- breathing-exercises-weed-withdrawal-anxiety
- cannabis-induced-anxiety
- does-weed-help-anxiety
- grounding-techniques-weed-withdrawal
- health-anxiety-weed-withdrawal
- manage-anxiety-without-weed
- quitting-weed-anxiety-disorder
- quitting-weed-anxiety-medication-ssri
- self-medicating-anxiety-with-weed
- therapy-quitting-weed-anxiety
- weed-and-anxiety
- weed-biphasic-effect-anxiety
- weed-generalized-anxiety-disorder
- weed-panic-attacks
- weed-paranoia
- weed-social-anxiety
- weed-tolerance-anxiety-stopped-working
- weed-withdrawal-anxiety
- weed-withdrawal-panic-attacks-night
- weed-withdrawal-work-anxiety
- withdrawal-anxiety-vs-real-anxiety
Cite This Study
https://rethinkthc.com/research/RTHC-07455APA
Reddy, Apoorva C; Hampton, John M; Park, Susan J; Dickerson, Faith; Shah, Janvi; Chewning, Betty; Schmitz, Natalie; Trentham-Dietz, Amy. (2025). Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.. Cancer medicine, 14(21), e71342. https://doi.org/10.1002/cam4.71342
MLA
Reddy, Apoorva C, et al. "Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.." Cancer medicine, 2025. https://doi.org/10.1002/cam4.71342
RethinkTHC
RethinkTHC Research Database. "Measuring the Effects of Cannabis on Anxiety and Depression ..." RTHC-07455. Retrieved from https://rethinkthc.com/research/reddy-2025-measuring-the-effects-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.